期刊文献+

单药替吉奥胶囊治疗老年晚期胃癌的临床观察 被引量:13

Clinical observation of S-1 capsule in the treatment of elderly patients with advanced gastric cancer
下载PDF
导出
摘要 目的:观察单药替吉奥胶囊治疗晚期胃癌的临床疗效及毒副反应。方法:选择50例经病理证实的老年晚期胃癌患者,随机分为治疗组32例及对照组18例。治疗组根据体表面积给予替吉奥胶囊治疗,对照组给予营养等最佳支持治疗。每2周期后行影像学检查评价疗效、记录不良反应及随访情况。结果:治疗组32例患者CR(完全缓解)0例,PR(部分缓解)10例,SD(病情稳定)12例,PD(病情进展)10例,临床总缓解率31.3%,临床获益率68.8%。治疗组中位无疾病进展时间及中位生存期分别为5.7及11.5个月,对照组分别为3.1及7.6个月。毒副反应主要为I-III度骨髓抑制、消化道反应、肝功能损伤及手足综合症。结论:单药替吉奥胶囊治疗老年晚期胃癌效果肯定,生活质量高、毒副作用小。 Objective:To evaluate the efficiency and toxicities of S-1 capsule in the treatment of elderly patients with advanced gastric cancer.Methods:Fifty elderly patients with advanced gastric cancer were divided into treatment group(32 cases) and control group(18 cases).Patients of treatment group were treated with S-l,patients of control group were given the best support treatment.After two consecutive treatment circles,the clinical efficacy,adverse effects and follow-up condition were evaluated.Results:In the treatment group,no case showed remission(CR),10 cases showed partial remission(PR),12 cases showed stable disease(SD),10 cases showed progressive disease(PD).The responsive rate(CR + PR) was 31.3%,the illness control rate(CR + PR + SD) was68.8%.The progression free survival(PFS) and median survival time(MST) in treatment group were 5.7 and11.5 months respectively,and 3.1 and 7.6 months in the control group respectively.The major adverse events were myelosuppression ranging from grade I to Ⅲ,disgusting damage of liver function and hand-foot syndrome.Conclusion:The S-l shows a positive effect for elderly patients with advanced gastric cancer.It can achieve a better quality of life and small side effects for the patients.
出处 《临床与病理杂志》 2016年第1期67-70,共4页 Journal of Clinical and Pathological Research
关键词 胃癌 老年 晚期 替吉奥 疗效 毒副反应 gastric cancer elder advanced s-1 efficiency toxicity
  • 相关文献

参考文献7

二级参考文献86

  • 1秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 2葛乃建,李苏宜.食管癌内科治疗研究新进展[J].东南大学学报(医学版),2007,26(3):237-240. 被引量:10
  • 3白坂哲彦 佃守犬山 夫他新规.经口抗癌剂TS-1(S-1).癌症化学疗法,2001,:855-864.
  • 4van Meerten E,Eskeus FA,van Gameren EC,et al.Firstline treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer:a phase Ⅱ study[J].Br J Cancer,2007,96(9):1348.
  • 5Lowy AM,Firdaus Ⅰ,Roychowdhury D,et al.A phase Ⅱ study of sequential neoadjuvant gemcitabine and paclitaxel,radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma[J].Am J Clin Oncol,2006,29(6):555.
  • 6Shirasaka T.Development history and concept of an oral anticancer agent S-1 (TS-1):its clinical usefulness and future vistas[J].Jpn J Clin Oncol,2009,39(1):2.
  • 7Casado E,Pfeiffer P,Feliu J,et al.UFT (tegafur-uracil)in rectal cancer[J].Ann Oncol,2008,19(8):1371.
  • 8Koizumi W,Boku N,Yamaguchi K,et al.Phase Ⅱ study of S-1 plus leucovorin in patients with metastatic colorectal cancer[J].Ann Oncol,2010,21(4):766.
  • 9Enzinger P C,Ryan D P,Clark J W,et al.Weekly docetaxel,cisplatin,and irinotecan (TPC):results of a multicenter phase Ⅱ trial in patients with metastatic esophagogastric cancer[J].Ann Oncol,2009,20(3):475.
  • 10Albertsson M,Johansson B,Friesland S,et al.Phase Ⅱ studies on docetaxel alone every third week,or weekly in combination with gemcitabine in patients with primary locally advanced,metastatic,or recurrent esophageal cancer[J].Med Oncol,2007,24(4):407.

共引文献95

同被引文献128

  • 1王利,魏品康,秦志丰,许玲,张玲珍,何金,李玉莉.榄香烯对耐药胃癌细胞的逆转实验研究[J].成都中医药大学学报,2005,28(2):51-53. 被引量:22
  • 2王子平,孙燕,张湘茹,张茂宏,王秀问,于学军,南克俊,李恩孝,刘基巍,高亚杰,关小倩,宋恕平,盛立军,王东林,王志新.多西他赛治疗晚期乳腺癌的临床研究[J].中华肿瘤杂志,2006,28(6):468-470. 被引量:70
  • 3谭广,王忠裕,王晓刚,程雷,殷朔.IL-23基因修饰的树突细胞疫苗联合β-榄香烯对小鼠胰腺癌生长的影响[J].癌症,2006,25(9):1082-1086. 被引量:19
  • 4Jemal A,Siegel R,Ward E,et al.Cancer statistics.2006[J].CA Cancer J Clin,2006,56(2):106-130.
  • 5Bruckner HW,Morris JC,Mansfield P.Neoplasms of the stomach.Cancer Medicine[M].5th ed.Hamilton:BC Decker,2000:1355-1390.
  • 6Alberts SR,Cervantes A,Vande Velde CJ,et al.Gastriccancer:epidemiology,pathology and treatment[J].Ann Oncol,2003,14(suppl 2):S31.
  • 7Malet-Martino M,Martino R.Clinical studies of three oralprodrugs of 5-fluorouracil(capecit abine,UFT,S21):a review[J].Oncologist,2002,7(4):288.
  • 8Tanaka F,Fukuse T,Wada H,et al.The history,mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J].Curr Pharm Biot echnol,2000,1(2):137.
  • 9Wesolowski R,Lee C,Kim R.Is there a role for second-line chemotherapy in adavanced gastric cancer?[J].Lancet On-col,2009,10:903-912.
  • 10Shirasaka T,Tsukuda M,Inuyama Y,et al.New oral anticancer drug,TS-1(S-1)from bench toclinic[J].Gan To Kagaku Ryoho,2001,28(6):855.

引证文献13

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部